- In April 2025, a study highlighted the optimization of cultured ELISpot/FluoroSpot technique for selective investigation of SARS-CoV-2 reactive central memory T cells. This advancement in methodology, particularly for detecting central memory T-cell IFNγ responses, emphasizes the balance between enhancing specific cognate central memory responses while limiting non-specific activation. This kind of research contributes to refining assay sensitivity and specificity in critical areas such as infectious disease monitoring
- In June 2022, BD and CerTest Biotec announced a partnership to develop a molecular diagnostic test for the Monkeypox virus. Utilizing BD MAX open system reagents, the collaboration aims to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAX System, enhancing diagnostic capabilities for this rare disease
- In April 2022, ProImmune Ltd. introduced a B-cell ELISpot assay service designed to evaluate B cell immune responses. This assay enables researchers to assess vaccine efficacy and therapeutic interventions by quantifying B cells producing specific antibodies in response to stimuli
- In May 2021, BD participated in virtual investor healthcare conferences, including the Bank of America Securities 2021 Virtual Healthcare Conference and the UBS Global Healthcare Virtual Conference. These engagements facilitated global visibility and such asly attracted new customers, contributing to enhanced future market revenue for the company.
- In 2022, Mabtech (Sweden) made ELISpot kits available in a 100-plate format, including pre-coated plates to save time and reduce assay variability. They also introduced the Human IL-21 analyte in two colors in their FluoroSpot Flex platform, showcasing ongoing product development aimed at improving efficiency and expanding multiplexing capabilities
